Department of Hematology and BMT, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, 64239, Tel-Aviv, Israel.
Curr Hematol Malig Rep. 2006 Dec;1(4):220-9. doi: 10.1007/s11899-006-0003-x.
The addition of rituximab to chemotherapy has substantially changed the treatment strategies for patients with B-cell lymphomas. Rituximab, combined with standard chemotherapy regimens, shows consistently improved results compared with chemotherapy alone and has been extensively employed in both newly diagnosed and relapsed patients with B-cell lymphoma. Because of its low toxicity profile and its potent antilymphoma activity mediated through direct apoptotic and indirect effector mechanisms, rituximab also has been actively incorporated into stem cell transplantation (SCT) protocols to attain a state of minimal disease, provide a safe and effective method for in vivo purging prior to autologous SCT, and promote graft-versus-lymphoma effects in allogeneic SCT. This review compiles the still immature but rapidly growing data on this combined modality.
利妥昔单抗联合化疗显著改变了 B 细胞淋巴瘤患者的治疗策略。与单纯化疗相比，利妥昔单抗联合标准化疗方案显示出一致的改善效果，已广泛应用于新诊断和复发的 B 细胞淋巴瘤患者。由于其低毒性特征以及通过直接凋亡和间接效应机制介导的强大抗淋巴瘤活性，利妥昔单抗也积极纳入干细胞移植 (SCT) 方案，以达到微小残留病状态，为自体 SCT 前提供安全有效的体内净化方法，并在异基因 SCT 中促进移植物抗淋巴瘤效应。这篇综述汇集了关于这种联合治疗模式的仍不成熟但快速增长的数据。
